Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Gastrointestinal 2Breast 2Thoracic 1Other solid neoplasm 1Head & Neck 1Genitourinary 1

Conditions

Prostatic Neoplasms 13Pancreatic Neoplasms 3Carcinoma, Renal Cell 3Breast Neoplasms 3Sarcoma, Ewing 2Ovarian Neoplasms 2Neoplasm Metastasis 2Colorectal Neoplasms 2Wilms Tumor 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Prostatic Diseases 1Prostate Cancer Metastatic 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Neoplasms 1Metastatic Castration Resistant Prostate Cancer (mCRPC) 1Kidney Neoplasms 1Hepatoblastoma 1Fanconi Anemia, Complementation Group D1 1Carcinoma, Transitional Cell 1Carcinoma, Ovarian Epithelial 1Adenocarcinoma 1

Interventions

pembrolizumab 35Nivolumab 14Docetaxel 11atezolizumab 10Paclitaxel 9Carboplatin 7Gemcitabine 6Cisplatin 6Trastuzumab 5Magnetic Resonance Spectroscopy 5Ipilimumab 5Fluorodeoxyglucose F18 5Cyclophosphamide 5Bevacizumab 5fludarabine 4avelumab 4Specimen Handling 4Psychiatric Rehabilitation 4Oxaliplatin 4Leucovorin 4Fluorouracil 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4cemiplimab 3Taxes 3Polymerase Chain Reaction 3Pemetrexed 3Irinotecan 3Gene Expression Profiling 3Early Intervention, Educational 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stomach Neoplasms × talazoparib × Genitourinary × Clear all
NCT04550494 2026-05-13

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

National Cancer Institute (NCI)

Phase 2 Recruiting
36 enrolled
BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡